transgenic mice

trans·gen·ic mice

(tranz'jen-ik),
Mice that have a piece of foreign DNA integrated into their genome.
References in periodicals archive ?
Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies: mice that generate antibodies comprised of two heavy chains and two light chains with fully human variable regions; and mice that generate novel "heavy chain only" antibodies.
ContraVir Pharmaceuticals announced that the peer-reviewed journal, PLOS ONE, has published ContraVir's research article entitled "The Cyclophilin Inhibitor CRV431 Inhibits Liver HBV DNA and HBsAg in Transgenic Mice." The article describes a study where Hepatitis B virus transgenic mice were treated with CRV431, a cyclophilin inhibitor; and/or tenofovir exalidex, a nucleotide prodrug.
Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies: (1) mice that generate antibodies comprised of two heavy chains and two light chains with fully human variable regions; and (2) mice that generate novel "heavy chain only" antibodies.
In this study, the effect of NCL on microRNA (miRNA) expression was evaluated by generating transgenic mice with myocardial overexpression of NCL and by analyzing microarrays of mature and precursor miRNAs from mice.
The study used APP/PS1 mice, which are transgenic mice that express human mutated genes that cause Alzheimer's.
The study used PS1 mice, which are transgenic mice that express human mutated genes that cause Alzheimer's.
While the mechanisms underlying the depressive phenotype observed in both HD patients and HD transgenic mice are not fully elucidated, deficits in hippocampal neuroplasticity, namely, hippocampal neurogenesis, are likely to contribute to these mood disturbances in HD.
Mitochondrial function in the brains of the transgenic mice normalized, as did in the heart.
Editas Medicine, Inc., a leading genome editing company, today announced results from a pre-clinical study in transgenic mice demonstrating dose-dependent, in vivo editing using EDIT-101, Editas Medicines pre-clinical product candidate for the treatment of Leber Congenital Amaurosis type 10 (LCA10).
To gain insights into that question, vCJD/BSE transmission studies in which either humanized overexpressing or knock-in transgenic mice were used have been performed (2,26-30).
APP transgenic mice (C57BL/6J-APP mice; n=16/group, 1-12 months) were obtained from the Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS&PUMC).
The 2.2-kb hGFAP promoter, generates transgenic mice (Zhuo et al., 1997; Nolte et al., 2001) with green fluorescence protein (GFP)-expressing astrocytes and allows the entire structure of astrocytes in a living brain to be visualized.